Topical clascoterone (Winlevi 1% cream, a first-in-class topical androgen-receptor inhibitor) gives adults with persistent acne a modest but durable non-antibiotic option. Revisited evidence shows lower lesion counts, similar 12-week results to two topical retinoids, and maintained tolerability with extended use. DailyMed lists Winlevi 1% cream as FDA-approved for acne vulgaris in patients 12 years and older, applied as a thin layer twice daily DailyMed drug listing. For adults facing repeated breakouts, that positions it as maintenance therapy rather than a quick spot fix.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- How does it act on adult skin?
- How much clearing can you expect?
- Can you stay on it long term?
- What are the side effects and cautions?
How does it act on adult skin?
An FDA approval review summarized by Cassiopea and Sun Pharma explains that clascoterone competes with androgens, especially DHT, for binding in sebaceous glands and hair follicles. That local block lowers sebum production and inflammation where acne starts.
Adults with persistent disease often cycle through clogged pores, tender red bumps, and flare-ups along the lower face and trunk. By targeting androgen signaling in skin, clascoterone addresses oil and inflammation without acting as an antibiotic or systemic hormone therapy. Skin esterases then convert it rapidly to inactive cortexolone, which limits systemic exposure.
How much clearing can you expect?
The Journal of Drugs in Dermatology reports two identical 12-week phase 3 trials in moderate-to-severe facial acne trial summary in the Journal of Drugs in Dermatology. Twice-daily clascoterone achieved treatment success in 18.4% versus 9.0% and 20.3% versus 6.5% against vehicle. Inflammatory and noninflammatory lesions fell significantly more with active treatment.
Those rates look modest alone, but they reflect strict success definitions after 12 weeks. A 2024 systematic review and meta-analysis in Dermatology and Therapy, described on Springer Nature Link, found no significant efficacy difference among clascoterone, trifarotene, and tazarotene for lesion-count reduction or treatment success at 12 weeks comparative meta-analysis in Dermatology and Therapy. For adults choosing among topicals, tolerability, cost, access, and fit with other products may matter more than small efficacy gaps.
Can you stay on it long term?
An open-label extension described by Healio Dermatology followed phase 3 completers for an additional 9 months. Participants applied clascoterone 1% to face and trunk twice daily, with efficacy and tolerability maintained over that period.
That pattern suits persistent adult acne, which needs steady control rather than short bursts. The 2024 American Academy of Dermatology acne guidelines, summarized by MeduGate, conditionally recommend topical clascoterone and emphasize multimodal non-antibiotic maintenance. Adults seeking to limit prolonged antibiotics gain another maintenance path to discuss with a dermatologist.
What are the side effects and cautions?
The Pharmaceuticals narrative review published by MDPI identifies local irritation, redness, pruritus, burning, and peeling as the most common harms MDPI Pharmaceuticals review. Systemic exposure stays low because skin esterases rapidly convert clascoterone to inactive cortexolone.
Under maximum-use testing, reversible HPA-axis suppression occurred in 1 of 20 adults and 2 of 22 adolescents, generally normalizing within about 4 weeks, according to Sun Pharma data presented at AAD and summarized by BioSpace and the MDPI review. The label warns about HPA suppression and hyperkalemia. Ask your dermatologist whether twice-daily clascoterone fits your current retinoid, benzoyl peroxide, or maintenance plan.
- Use a thin layer twice daily on prescribed areas only
- Watch for ongoing burning, peeling, redness, or itch that spreads or worsens
- Seek prompt care for signs of adrenal disruption, unusual fatigue, dizziness, nausea, or electrolyte symptoms
- Tell your prescriber about corticosteroids, potassium risks, and trunk application plans
You Might Also Like
- Topical Clascoterone Evidence Revisited in 2026: Study Design and Evidence Limits for Adults With Persistent Acne
- Topical Hormonal Acne Treatments in a 2026 Review: Study Design and Evidence Limits for Adults With Persistent Acne
- Milk, Dairy, and Acne Evidence Revisited in 2026: Questions Adults With Persistent Acne Can Ask a Dermatologist